---
layout: full_article
title: "Increase of Carotid Intima-Media Thickness and Reduction of Carotid Artery Lumen Diameter in Breast Cancer Patient Before and After Chemotherapy"
author: "Inez Kartika, Made Widhi Asih, Elysanti Dwi Martadiani, Pande Putu Yuli Anandasari, Putu Patriawan, I Gde Raka Widiana"
categories: jbn
canonical_url: https://jurnal.harianregional.com/jbn/full-80731 
citation_abstract_html_url: "https://jurnal.harianregional.com/jbn/id-80731"
citation_pdf_url: "https://jurnal.harianregional.com/jbn/full-80731"  
comments: true
---

<img src="https://jurnal.harianregional.com/media/80731-1.jpg" alt="" style="width:70pt;height:27pt;">
<p><span class="font0" style="font-weight:bold;">DIRECTORY OF</span></p>
<p><span class="font0" style="font-weight:bold;">OPEN ACCESS</span></p>
<p><span class="font0" style="font-weight:bold;">JOURNALS</span></p>
<div>
<p><span class="font3">P-ISSN:</span><a href="http://u.lipi.go.id/1481204884"><span class="font3"> 2548-5962</span></a></p>
<p><span class="font3">E-ISSN:</span><a href="http://u.lipi.go.id/1483969293"><span class="font3"> 2548-981X</span></a></p>
</div><br clear="all">
<div><a name="caption1"></a>
<h1><a name="bookmark0"></a><span class="font2" style="font-weight:bold;"><a name="bookmark1"></a>ΘB^I≡L ARTICLE</span></h1>
</div><br clear="all">
<div>
<p><a href="https://ojs.unud.ac.id/index.php/jbn"><span class="font3">https://ojs.unud.ac.id/index.php/jbn</span></a></p>
</div><br clear="all">
<div><img src="https://jurnal.harianregional.com/media/80731-2.jpg" alt="" style="width:103pt;height:65pt;">
</div><br clear="all">
<p><span class="font7" style="font-weight:bold;">Increase of Carotid Intima-Media Thickness and Reduction of Carotid Artery</span></p>
<p><span class="font7" style="font-weight:bold;">Lumen Diameter in Breast Cancer Patient Before and After Chemotherapy</span></p>
<p><span class="font5" style="font-weight:bold;">Inez Kartika<sup>1*</sup>, Made Widhi Asih<sup>2</sup>, Elysanti Dwi Martadiani<sup>2</sup>, Pande Putu Yuli Anandasari<sup>2</sup>, Putu Patriawan<sup>2</sup>, I Gde Raka Widiana<sup>3</sup></span></p>
<ul style="list-style:none;"><li>
<p><span class="font4"><sup>1</sup> &nbsp;&nbsp;&nbsp;Resident of Radiology Department Faculty of Medicine Udayana University, Sanglah General Hospital, Bali.</span></p></li>
<li>
<p><span class="font4"><sup>2</sup> &nbsp;&nbsp;&nbsp;Staff of Radiology Department Faculty of Medicine Udayana University, Sanglah General Hospital, Bali.</span></p></li>
<li>
<p><span class="font4"><sup>3</sup> &nbsp;&nbsp;&nbsp;Staff of Internal Medicine Department Faculty of Medicine Udayana University, Sanglah General Hospital, Bali.</span></p></li></ul>
<p><span class="font4">* Corresponding author: </span><a href="mailto:inez.kartika@yahoo.com"><span class="font4">inez.kartika@yahoo.com</span></a><span class="font4">.</span></p>
<p><span class="font5" style="font-weight:bold;">ABSTRACT</span></p>
<p><span class="font5" style="font-weight:bold;">Background: </span><span class="font5">Increasing the number of cancer survivors motivates clinical practitioners to focus on the chronic effect of chemotherapy agents, especially those with vascular toxicity effects, which may attenuate the incidence of thrombosis and atherogenesis. Ultrasonography examination on carotid intima-media thickness (C-IMT) provides accurate results in evaluating atherosclerotic. The purposes of this research are to find out any structural changes of the carotid artery, especially atherosclerosis changes in breast cancer patients after chemotherapy. </span><span class="font5" style="font-weight:bold;">Methods</span><span class="font5">: Analytic cross-sectional study using a pre-post test group design in breast cancer patients. Eligible subjects undergo carotid ultrasonography examination before chemotherapy and after completing the three cycles of chemotherapy for the second exam. The examination was performed with the same USG machine, high-frequency linear transducer (&gt;7mHz) in B-mode under the auspices of two reputable radiologist consultants. </span><span class="font5" style="font-weight:bold;">Results: </span><span class="font5">Total patients are 26, mean of age (year) is 47.15 ± 8.11. The most dominant histopathology finding is invasive carcinoma nonspecific type, in 24 patients (92.4%), and the disease stage is in stadium III in 14 patients (53.9%). Mean C-IMT (mm) prior chemotherapy is 0.51 ± 0.06 and after chemotherapy is 0.58 ± 0.05, there is an increase of 0.07 ± 0.06 (p&lt;0.0001). Carotid artery lumen diameter (mm) before</span></p>
<p><span class="font5">chemotherapy is 4.05 ± 0.66 and after chemotherapy is 3.90 ± 0.73, so there is a decrease of 0.16 ± 0.40 (p =0.057). </span><span class="font5" style="font-weight:bold;">Conclusion: </span><span class="font5">There is a statistically significant increase in intintima-mediaickness of the carotid wall of breast cancer patients after chemotherapy, consisting of chemotherapy-induced atherosclerosis.</span></p>
<p><span class="font5" style="font-weight:bold;">Keywords: </span><span class="font5">ultrasonography, C-IMT, chemotherapy, breast cancer.</span></p>
<p><span class="font5" style="font-weight:bold;">DOI: https:// doi.org/10.24843/JBN.2022.v06.i01.p02</span></p>
<h2><a name="bookmark2"></a><span class="font6" style="font-weight:bold;"><a name="bookmark3"></a>INTRODUCTION</span></h2>
<p><span class="font6">The survival of cancer patients is currently an interesting topic to be studied, researched, and developed. There is a noticeable increase in cancer survival rates internationally, supported by early detection, better chemotherapy regimens, and especially collaborative multidisciplinary management approaches. In January 2016, more than 2.5 million women living in the US with a history of breast cancer, with a lower life expectancy than the general healthy population.<sup>1,2</sup> These findings increase the vigilance of clinicians for</span></p>
<p><span class="font6">advanced chronic effects of breast cancer therapy, especially chemotherapeutic agents.</span></p>
<p><span class="font6">One distinct consequence of current cancer therapy is cognitive dysfunction after chemotherapy often referred to as “chemobrain.” <sup>3</sup> It is estimated that about 18 to 78% of breast cancer patients have this cognitive dysfunction after the initiation of chemotherapy therapy, but the certain pathophysiology is not fully understood. <sup>4</sup>Cognitive dysfunction in the general population is closely related to various cerebrovascular disorders, the especially</span></p>
<p><span class="font6">microvascular disruption that causes hypoperfusion, demyelination and ischaemic lession in white matter.<sup>5</sup> Carotid atherosclerosis is also a major risk factor for the cerebrovascular disorder, and it can be used to predict the risk of cognitive impairment.<sup>6</sup></span></p>
<p><span class="font6">The main undesirable well-known side effects of chemotherapy is vascular toxicity in which endothelial dysfunction can occur, loss of vasorelaxant ability, suppression of antiinflammatory function and vascular reparation.<sup>7</sup> These impairments are able to accelerate the occurrence of hypertension, thrombosis and atherogenesis, which are risk factors for cardiovascular disease. The prevalence of arterial thromboembolism in cancer patients who undergo chemotherapy is 1.7.<sup>8</sup> However, it must be understood that chemotherapy works systemically; it is not possible to attack only the cardiovascular course exclusively. Certainly, it will also interfere with the cerebrovascular course.</span></p>
<p><span class="font6">Atherosclerosis, alteration in carotid artery wall intima-media thickness (C-IMT), can be used as an early marker for cognitive dysfunction in breast cancer patients receiving chemotherapy. Color Doppler ultrasound examination is proficient in non-invasive evaluation of carotid arteries by assessing C-IMT and the stenosis of the internal carotid artery as well as the common carotid artery.<sup>9,10 </sup>In this study, the author intends to prove whether there are structural changes in the carotid arteries, especially atherosclerosis, in breast cancer patients who received chemotherapy through measurement and examination of carotid ultrasound.</span></p>
<h2><a name="bookmark4"></a><span class="font6" style="font-weight:bold;"><a name="bookmark5"></a>METHODS</span></h2>
<p><span class="font6">This study uses an analytic cross-sectional study with a pre-post test group design from April to September 2019 at RSUP Sanglah Denpasar. The research subjects were breast</span></p>
<p><span class="font6">cancer patients who underwent chemotherapy. Patients with uncontrolled diseases or comorbidity such as hypertension, dyslipidemia, stroke and refuse to participate after informed consent were excluded from the study. We calculated the sample size with estimated standart deviation difference of mean C-IMT thickness pre and post test was 0.13,<sup>11,12</sup> and we got an estimate of the minimum sample size needed is 26 people.</span></p>
<p><span class="font6">After obtaining ethical clearance and permission from the Research and Development Unit of Faculty of Medicine Udayana University / Sanglah Hospital, No.161/UN14.2.2.VII.14/LP/2019, we continued with subject collecting and explained the whole process of this study, including the aims and benefits for the subjects, possible complications, and ended with signing the informed consent.</span></p>
<p><span class="font6">Carotid ultrasound examination is done twice, before and after chemotherapy, on the right and left carotid arteries, using the GE LOGIC<sup>TM</sup> S7 ultrasound machine, with high-frequency (&gt;7 MHz) linear transducer in B-mode by radiology specialist consultant. Measurement of the carotid intima-media thickness (C-IMT) is done semiautomatic at 3 spots on both sides of the carotid artery in the supine position and the head-turning contralaterally from the examined site. The three spots are the common carotid artery (10 mm before the bulb), the bulb (5-10 mm cranial bulb), and the internal carotid artery (10 mm after carotid branching) at the free plaque part. The mean C-IMT is calculated from the mean value of the six points measured. The maximum C-IMT is the largest value among the six points. The second carotid ultrasound measurement is performed after the third cycle of chemotherapy take place with the same measurement procedure as explained.</span></p>
<p><span class="font6">Statistical analysis is done using IBM SPSS statistics 23.0. For numerical data, data normality analysis was performed using the Shapiro-Wilk test. The data is normally distributed if p&gt;0.05. Bivariate analysis was used to find the risk factor affecting the C-IMT before and after chemotherapy. We use T-Paired test for analysis of C-IMT before and after chemotherapy.</span></p>
<p><span class="font6">Since there are several variables that affect the C-IMT, a multivariate analysis test was carried out, namely covariance analysis (ANCOVA) for age, cancer stage, histopathology type and pre-post</span></p>
<p><span class="font6">chemotherapy group. Statistical test results were significant if p&lt;0.05.</span></p>
<h2><a name="bookmark6"></a><span class="font6" style="font-weight:bold;"><a name="bookmark7"></a>RESULTS</span></h2>
<p><span class="font6">This study engaged 26 breast cancer patients who underwent chemotherapy treatment. We also studied an interobserver of the C-IMT measurement result for conformity value between the two operators. There is no difference (bias) between operator 1 and 2 with all p values &gt;0.05 for the thickness measurement of the common carotid artery, bulbous and internal carotid artery. The characteristics of the subjects are described in </span><span class="font6" style="font-weight:bold;">Table 1</span><span class="font6">.</span></p>
<div>
<p><span class="font5" style="font-weight:bold;">Table 1. </span><span class="font5">Characteristics of research subjects (n=26)</span></p>
<table border="1">
<tr><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">Variable</span></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">Characteristics of research subjects</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font5">Age (years) <sup>a</sup></span></p>
<p><span class="font5">Body mass index (kg/ m<sup>2</sup>) <sup>a</sup></span></p>
<p><span class="font5">Types of chemotherapy <sup>b</sup></span></p>
<p><span class="font5">CAF</span></p>
<p><span class="font5">CEF</span></p>
<p><span class="font5">Paclitaxel Doxorubicin</span></p>
<p><span class="font5">Paclitaxel Epirubicin</span></p>
<p><span class="font5">Doxorubicin cyclophosphamide</span></p>
<p><span class="font5">Histopathology <sup>b</sup></span></p>
<p><span class="font5">Invasive carcinoma non-specific type</span></p>
<p><span class="font5">Adenocarcinoma</span></p>
<p><span class="font5">Mixed type invasive and lobular carcinoma Stadium <sup>b</sup></span></p>
<p><span class="font5">I</span></p>
<p><span class="font5">II</span></p>
<p><span class="font5">III</span></p>
<p><span class="font5">IV</span></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font5">47.15 ± 8.11</span></p>
<p><span class="font5">24.38 ± 3.36</span></p>
<p><span class="font5">9 (34.6%)</span></p>
<p><span class="font5">5 (19.2%)</span></p>
<p><span class="font5">8 (30.8%)</span></p>
<p><span class="font5">3 (11.5%)</span></p>
<p><span class="font5">1 (3.8%)</span></p>
<p><span class="font5">24 (92.4%)</span></p>
<p><span class="font5">1 (3.8%)</span></p>
<p><span class="font5">1 (3.8%)</span></p>
<p><span class="font5">1 (3.8%)</span></p>
<p><span class="font5">7 (26.9%)</span></p>
<p><span class="font5">14 (53.9%)</span></p>
<p><span class="font5">4 (15.4%)</span></p>
<p><span class="font5" style="font-weight:bold;">C-IMT before &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C-IMT after</span></p>
<p><span class="font5" style="font-weight:bold;">chemotherapy (mm) &nbsp;&nbsp;chemotherapy</span></p>
<p><span class="font5" style="font-weight:bold;">(mm)</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font5">Right common carotid artery <sup>a</sup></span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.49 ± 0.061</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.54 ± 0.072</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">Right bulb <sup>a</sup></span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.54 ± 0.085</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.65 ±0.133</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">Right internal carotid artery <sup>a</sup></span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.49 ± 0.089</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.52 ± 0.128</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">Left common carotid artery <sup>a</sup></span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.49 ± 0.087</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.58 ± 0.079</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">Left bulb <sup>a</sup></span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.55 ± 0.138</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.63 ± 0.118</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">Left internal carotid artery <sup>a</sup></span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.52 ± 0.706</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.57 ± 0.101</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">C-IMT average <sup>a</sup></span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.51 ± 0.496</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.56 ± 0.055</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">Internal carotid arterydiameter <sup>a</sup></span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">4.05 ±0.660</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">3.9 ± 0.731</span></p></td></tr>
</table>
<p><span class="font4"><sup>a</sup> Mean ± standard deviation; <sup>b</sup> Frequency (%); CAF: cyclophosphamide doxorubicin 5-fluorouracil; CEF: cyclophosphamide epirubicin 5-fluorouracil</span></p>
</div><br clear="all">
<p><span class="font6">All subjects who participated in this study underwent doppler carotid ultrasound examination twice, before and after chemotherapy. Data characteristic is shown in </span><span class="font6" style="font-weight:bold;">Table 1</span><span class="font6">. The values of C-IMT average and internal carotid artery diameter were normally distributed in the Shapiro-Wilk normality test (p&gt;0.05), so we continued with the bivariate analysis of T-paired test.</span></p>
<p><span class="font6">In </span><span class="font6" style="font-weight:bold;">Table 2</span><span class="font6">, the mean of average C-IMT before chemotherapy was 0.51 ± 0.06 mm, after chemotherapy 0.58 ± 0.05 mm with a significant increase of 0.68 ± 0.06 mm (p&lt;0.0001). The reduction in diameter of the internal carotid artery before chemotherapy was 4.05 ± 0.66 mm, after chemotherapy, it became 3.90 ± 0.73 mm, resulting in decreased in diameter by 0.16 ± 0.40 mm, but statistically, it was not significant with p=0.057.</span></p>
<p><span class="font6">To determine which variables (chemotherapy type, age, histopathology, and cancer stadium) affects the C-IMT and internal carotid diameter before and after chemotherapy, multivariate analysis was performed with covariance analysis (ANCOVA) (</span><span class="font6" style="font-weight:bold;">Table 3</span><span class="font6">).</span></p>
<p><span class="font6">Analysis of covariance (ANCOVA) on the C-IMT thickness before and after chemotherapy shows that chemotherapy regiment and age affect the thickening of C-IMT thickness (p &lt;0.05). ANCOVA also shows that the reduction in internal carotid artery lumen diameter is not affected by chemotherapy, age, histopathology, and cancer stadium. This might be influenced by other variables that cannot be identified in this study.</span></p>
<p><span class="font5" style="font-weight:bold;">Table 2. </span><span class="font5">Average C-IMT and diameter of internal carotid artery values</span></p>
<table border="1">
<tr><td rowspan="2" style="vertical-align:top;"></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">Chemotherapy</span></p></td><td rowspan="2" style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">difference</span></p></td><td rowspan="2" style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">p-value</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">Before</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">After</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">C-IMT average (mm)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.51 ± 0.05</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.58 ± 0.06</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.07 ± 0.06</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">&lt;0.0001</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font5">Internal carotid artery diameter (mm)</span></p></td><td style="vertical-align:top;">
<p><span class="font5">4.05 ± 0.66</span></p></td><td style="vertical-align:top;">
<p><span class="font5">3.90 ± 0.73</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.16 ± 0.40</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.057</span></p></td></tr>
</table>
<p><span class="font4">C-IMT: carotid intima-media thickness</span></p>
<p><span class="font5" style="font-weight:bold;">Table 3. </span><span class="font5">Covariance analysis of C-IMT and diameter of internal carotid artery</span></p>
<table border="1">
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">Variable</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">F</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">p-value</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">C-IMT</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">Chemotherapy type</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">23.11</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">&lt;0.0001*</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font5">Age (years)</span></p></td><td style="vertical-align:top;">
<p><span class="font5">4.954</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.031*</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font5">Histopathology</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.370</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.546</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font5">Cancer stadium</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.064</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.802</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">Internal carotid artery</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">Chemotherapy type</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.686</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">0.412</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font5">diameter</span></p></td><td style="vertical-align:top;">
<p><span class="font5">Age (years)</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.350</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.557</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font5">Histopathology</span></p></td><td style="vertical-align:top;">
<p><span class="font5">3.585</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.064</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font5">Cancer stadium</span></p></td><td style="vertical-align:top;">
<p><span class="font5">1.015</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.319</span></p></td></tr>
</table>
<p><span class="font4">C-IMT: carotid intima-media thickness</span></p>
<h2><a name="bookmark8"></a><span class="font6" style="font-weight:bold;"><a name="bookmark9"></a>DISCUSSION</span></h2>
<p><span class="font6">The subjects collected in this study is 26 sample with diagnosis of breast cancer. The average age of the patients is 47.15 ± 8.11 years, consistent with the result of a previous study conducted by Karima, et al who reported that the average age of women with breast</span></p>
<p><span class="font6">cancer in Dr. Cipto Mangunkusumo National Public Hospital Jakarta is 47.53 ± 10.21 years old. <sup>13</sup></span></p>
<p><span class="font6">The distribution of subjects based on histopathological type showed the dominance of Invasive Carcinoma of no special type (NST) in 24 subjects (92.4%), followed by</span></p>
<p><span class="font6">adenocarcinoma and mixed types of invasive-globular carcinoma, each of which consisted of 1 person (3.8%). This data is in line with the findings of two previous studies at Sanglah Hospital in 2002-2012 (81.9%) and 20142016 (96.2%), that Invasive Carcinoma of no special type (NST) is the most common histopathology type that occurs in cancer patient, especially in the Balinese population.<sup>14,15</sup></span></p>
<p><span class="font6">These previous studies also find that most of the breast cancer patients seeking treatment at Sanglah Hospital were patients who had been diagnosed with stage III B cancer. The most common stage of breast cancer in this study is stage III, amounting to 14 patients (53.9%) with 9 patients in stage III b, 5 patients in stage IIIa. The same finding was also obtained by Kusumadjayanti, et al who stated that from the year 2010 until 2011, dr. Hasan Sadikin Public hospital’s breast cancer patients are often diagnosed at stage III.<sup>16</sup></span></p>
<p><span class="font6">The type of chemotherapy most widely used in this study was CAF (Cyclophosphamide Doxorubicin 5-Fluorouracil), amounting to 34.6%, followed by CEF (Cyclophosphamide Epirubicin 5-Fluorouracil). Chemotherapeutic agents cause an increased incidence of cardiovascular disturbance and atherosclerotic<sup>17</sup>, but there are no available studies that state which agents greatly affect the process of atherosclerotic, whereas doxorubicin is widely known to have cardiotoxic effect so that electrocardiographic examination should be examined inpatient receiving treatment with doxorubicin.<sup>18</sup></span></p>
<p><span class="font6">The mean C-IMT before chemotherapy is 0.51 ± 0.05 mm, after chemotherapy is 0.58 ± 0.06 mm, with a significant increase of 0.07 ± 0.06 mm (p&lt;0.0001). Whereas in the analysis of the reduction in internal carotid artery lumen diameter before chemotherapy is 4.05 ± 0.66 mm, after chemotherapy is 3.90 ± 0.73 mm, the reduction in lumen diameter is 0.16 ±</span></p>
<p><span class="font6">0.40 mm, however, this finding is not statistically significant (p = 0.057).</span></p>
<p><span class="font6">Covariance analysis (ANCOVA) of the C-IMT thickness before and after chemotherapy with controlled variables such as age, histopathology and cancer stage were also carried out. There was a significant effect on the group of before and after chemotherapy, also on the group of age. As for the diameter of the internal carotid lumen, it does not appear to be affected by these variables. This can be caused by other variables that were not identified in this study.</span></p>
<p><span class="font6">To date, to the best of the author’s knowledge, there have been no other studies that have focused on the increase of C-IMT thickness, which is assessed by ultrasound semiautomatic B-mode that can directly demonstrate atherosclerotic changes of blood vessel wall of breast cancer patients after chemotherapy. The existing publication only states a relation of new atherosclerotic formation and heart problems after chemotherapy treatment, in line with the findings in our study.<sup>17</sup></span></p>
<p><span class="font6">In our study, an increase in the C-IMT thickness seemed to be influenced by chemotherapy. In practice, several journals also state that 5-Fluorouracil and Cisplatin have an effect on vascular toxicity due to endothelial dysfunction, loss of vasorelaxant effect and suppression of anti-inflammatory function and reparation function, these cause an increase in thrombosis and atherogenesis.<sup>19,20</sup> Atherosclerosis of the carotid artery is a major risk of cerebrovascular disorder and can be used to predict the risk of cognitive impairment.<sup>6</sup></span></p>
<p><span class="font6">Age was also found to be a variable that affected the increase in C-IMT thickness. As we know, atherosclerosis is one of the degenerative signs that increases with age. This finding is in line with the study of a large cohort group which found that there was a</span></p>
<p><span class="font6">projected increase in C-IMT of 0.01 mm/year in men and women.<sup>21</sup></span></p>
<h2><a name="bookmark10"></a><span class="font6" style="font-weight:bold;"><a name="bookmark11"></a>CONCLUSION</span></h2>
<p><span class="font6">From the results described above, all findings confirm the occurrence of chemotherapy-induced atherosclerosis, where there is an increase in the C-IMT thickness of breast cancer patients after chemotherapy, which is statistically significant.</span></p>
<p><span class="font6">For further research, we recommend that the research be conducted with more subjects, more variables, a longger period of time, one type of chemotherapy regimen, and a narrower age range. Doppler carotid ultrasound can be added as a routine follow up examination in breast cancer patients undergoing chemotherapy to reduce morbidity and mortality from related atherosclerotic disease.</span></p>
<h2><a name="bookmark12"></a><span class="font6" style="font-weight:bold;"><a name="bookmark13"></a>DISCLOSURE</span></h2>
<p><span class="font6">There are no financial conflicts of interest to disclose.</span></p>
<h2><a name="bookmark14"></a><span class="font6" style="font-weight:bold;"><a name="bookmark15"></a>REFERENCES</span></h2>
<ul style="list-style:none;"><li>
<p><span class="font6">1. &nbsp;&nbsp;&nbsp;American Cancer Society. </span><span class="font6" style="font-style:italic;">Breast Cancer</span></p></li></ul>
<p><span class="font6" style="font-style:italic;">Facts &amp;&nbsp;Figures 2017-2018</span><span class="font6">. American Cancer Society, Inc [serial online] 2017 [cited 2018 October 22]. Available from: </span><a href="https://www.cancer.org/content/%20cancer/en/search.html?q=Breas%20t+Cancer+Facts+&amp;+Figures+2017-2018"><span class="font6">https://www.cancer.org/content/</span></a><span class="font6"> </span><a href="https://www.cancer.org/content/%20cancer/en/search.html?q=Breas%20t+Cancer+Facts+&amp;+Figures+2017-2018"><span class="font6">cancer/en/search.html?q=Breast+Cancer+</span></a><span class="font6"> </span><a href="https://www.cancer.org/content/%20cancer/en/search.html?q=Breas%20t+Cancer+Facts+&amp;+Figures+2017-2018"><span class="font6">Facts+%26+Figures+2017-2018.</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font6">2. &nbsp;&nbsp;&nbsp;Schonberg MA, Marcantonio ER, Ngo L, et al. Causes of Death and Relative survival of Older Woman after Cancer Diagnosis. </span><span class="font6" style="font-style:italic;">J Clin Oncol</span><span class="font6">. 2011;29:1570-7.</span></p></li>
<li>
<p><span class="font6">3. &nbsp;&nbsp;&nbsp;Wang XM, Walitt B, Saligan L, et al. Chemobrain: A Critical review and causal hypothesis of Link between cytokines and epigenetic reprogramming associated with chemotherapy. </span><span class="font6" style="font-style:italic;">Cytokine</span><span class="font6">. 2015;72:86-96.</span></p></li>
<li>
<p><span class="font6">4. &nbsp;&nbsp;&nbsp;Ahles TA, Root JC, Ryan EL. Cancer-and Cancer Treatment-Associated Cognitive</span></p></li></ul>
<p><span class="font6">Change: An update on the State of the Science. </span><span class="font6" style="font-style:italic;">J Clin Oncol</span><span class="font6">. 2012;30:3675-86.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font6">5. &nbsp;&nbsp;&nbsp;Cicconetti P, Riolo N, Priami C, et al. Risk Factor For Cognitive Impairement. </span><span class="font6" style="font-style:italic;">Refenti Prog Med</span><span class="font6">. 2004;95:535-45.</span></p></li>
<li>
<p><span class="font6">6. &nbsp;&nbsp;&nbsp;Chen WH, Jin W, Lyu PY, et al. Carotid Atherosclerosis and Cognitive Impairment in Nonstroke Patients. </span><span class="font6" style="font-style:italic;">Chin Med J</span><span class="font6">. 2017;130:2375‑9.</span></p></li>
<li>
<p><span class="font6">7. &nbsp;&nbsp;&nbsp;Cameron AC, Touyz RM, Lang NN. Vascular Complication of Cancer Chemotherapy. </span><span class="font6" style="font-style:italic;">Can J &nbsp;&nbsp;Cardiol</span><span class="font6">.</span></p></li></ul>
<p><span class="font6">2016;32:852-62.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font6">8. &nbsp;&nbsp;&nbsp;Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic Event in Patient with metastatic carcinoma treated with Chemotherapy and Bevacizumab. </span><span class="font6" style="font-style:italic;">J Natl Cancer Inst</span><span class="font6">. 2007;99:1232-9.</span></p></li>
<li>
<p><span class="font6">9. &nbsp;&nbsp;&nbsp;Nezu T, Hosomi N, Aoki S, et al. Carotid Intima-Media &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thickness &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for</span></p></li></ul>
<p><span class="font6">Atherosclerosis. </span><span class="font6" style="font-style:italic;">J Atheroscler Thromb</span><span class="font6">. 2016;23:18-31.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font6">10. &nbsp;&nbsp;&nbsp;Thamasebpour HR, Buckley AR, Cooperberg PL, et al. Sonographic Examination of The Carotid Arteries. </span><span class="font6" style="font-style:italic;">RadioGraphics</span><span class="font6">. 2005;25:1561-75.</span></p></li>
<li>
<p><span class="font6">11. &nbsp;&nbsp;&nbsp;Dallal GE. </span><span class="font6" style="font-style:italic;">What Underlies Sample Size Calculations</span><span class="font6">. The Little Handbook of Statistical Practice [serial online] 2012 [cited 2018 October 28]. Available from: </span><a href="http://www.jerrydallal.com/LHSP/sizenot"><span class="font6">http://www.jerrydallal.com/LHSP/sizenot</span></a><span class="font6"> es.htm.</span></p></li>
<li>
<p><span class="font6">12. &nbsp;&nbsp;&nbsp;Saxena Y, Saxena V, Mittal M, et al. AgeWise association of Carotid Intima Media Thickness in Ischemic stroke. </span><span class="font6" style="font-style:italic;">Ann Neurosci</span><span class="font6">. 2017;24:4-11.</span></p></li>
<li>
<p><span class="font6">13. &nbsp;&nbsp;&nbsp;Karima UQ, Wahyono TYM. Faktor-faktor yang berhubungan dengan kejadian kanker payudara wanita di Rumah Sakit Umum Pusat Nasional dr. Cipto Mangunkusuma Jakarta tahun 2013. [</span><span class="font6" style="font-style:italic;">tesis</span><span class="font6">]. Jakarta: Universitas Indonesia; 2013.</span></p></li>
<li>
<p><span class="font6">14. &nbsp;&nbsp;&nbsp;Hartaningsih NMD, Sudarsa IW. Kanker Payudara Pada Wanita Usia Muda di Bagian Bedah Onkologi Rumah Sakit Umum Pusat Sanglah Denpasar tahun 2002-2012. </span><span class="font6" style="font-style:italic;">E-Jurnal Medika Udayana</span><span class="font6">. 2014;3:1-14.</span></p></li>
<li>
<p><span class="font6">15. &nbsp;&nbsp;&nbsp;Primadanti SJ, Setiawan IGB. Prevalensi kanker payudara subtipe triple negative pada wanita usia muda di Bali periode Januari 2014-Oktober 2016. </span><span class="font6" style="font-style:italic;">E-Jurnal Medika</span><span class="font6">. 2018;7:87-90.</span></p></li>
<li>
<p><span class="font6">16. &nbsp;&nbsp;&nbsp;Kusumadjayanti N, Badudu DF, Hernowo BS. Characteristics of patients with estrogenreceptor &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ER)-negative,</span></p></li></ul>
<p><span class="font6">progesterone receptor(PR)-negative, and HER2-negative invasive breast cancer in Dr. Hasan Sadikin General Hospital, Bandung, Indonesia from 2010 to 2011. </span><span class="font6" style="font-style:italic;">Althea Medical Journal</span><span class="font6">. 2015;2:391-4.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font6">17. &nbsp;&nbsp;&nbsp;Min SS, Wierzbicki A. Radiotherapy, Chemoteraphy and atherosclerosis. </span><span class="font6" style="font-style:italic;">Curr Opin Cardiol</span><span class="font6">. 2017;32:441-7.</span></p></li>
<li>
<p><span class="font6">18. &nbsp;&nbsp;&nbsp;Cai F, Luis MAF, Lin X, et al. Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: &nbsp;&nbsp;preventive strategies and</span></p></li></ul>
<p><span class="font6">treatment. </span><span class="font6" style="font-style:italic;">Mol Clin Oncol</span><span class="font6">. 2019;11:15-23.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font6">19. &nbsp;&nbsp;&nbsp;Daher IN, Yeh ETH. Vascular complication of selected cancer therapies. </span><span class="font6" style="font-style:italic;">Nat Clin Pract Cardiovasc Med</span><span class="font6">. 2008;5:797-805.</span></p></li>
<li>
<p><span class="font6">20. &nbsp;&nbsp;&nbsp;Herrmann J, Yang EH, Iliescu C, et al. Vascular Toxicities of cancer therapies. </span><span class="font6" style="font-style:italic;">Circulation</span><span class="font6">. 2016;133:1272-89.</span></p></li>
<li>
<p><span class="font6">21. &nbsp;&nbsp;&nbsp;Boulos MN, Gardin JM, Malik S, et al. Carotid Plaque Characterization, Stenosis, and Intima-Media Thickness According to Age and Gender in a large Registry Cohort. </span><span class="font6" style="font-style:italic;">Am J Cardiol</span><span class="font6">. 2016;117:1185-91.</span></p></li></ul>
<p><span class="font5">14</span></p>